Glenmark’s Ryaltris - nasal spray, ready for Russia
Glenmark Pharmaceuticals Ltd. a research-led Worldwide Integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., obtained marketing approval in the Ministry of Health of the Russian Federation for its revolutionary Ryaltris® Nasal Spray - a novel fixed-dose combination nasal spray.
This paves the way for commercialization of Ryaltris® in Russia which is anticipated to be made available to Patients in the country in Q1 FY 2021-22.
Ryaltris® (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg), is suggested for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. Ryaltris® alleviates symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, itching, as well as itchy, red and watery eyes.
In Russia, allergic rhinitis affects 10-20% of the Populace on average, with certain areas having a greater Prevalence rate of 18 - 38%. Allergic rhinitis can impact a person's quality of life and cause functional impairments, as well as increase the possibility of getting asthmai.
"Glenmark has built strong capabilities in the area of respiratory disorder and is among the leading players Inside this therapy area across several markets worldwide. Russia is among the key markets for us and we're Always looking to expand our product portfolio. We are thrilled to receive an endorsement for Ryaltris® Nasal spray from the Russian industry. This new revolutionary addition to our portfolio is Still Another Significant step in Strengthening Glenmark's respiratory attention in Russia and the CIS region. Glenmark has a powerful established Presence in Russia for over 30 decades, which will enable us to direct the commercialization of the product from the country. We anticipate being able to make this revolutionary product accessible to patients in Russia as Soon as possible," said Csaba Kantor, Senior Vice President - Russia & CIS region, Glenmark Pharmaceuticals.